Risedronic acid abrogates anastrozole-induced bone loss

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1620, 2008-01, pp. : 12-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anastrozole-related bone loss "manageable"

By  

Reactions Weekly, Vol. 1, Iss. 1326, 2010-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Risedronic acid prevents bone loss in postmenopausal women with breast cancer, with or without aromatase inhibitor (AI) therapy,

By  

Inpharma, Vol. 1, Iss. 1637, 2008-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

Anastrozole use appears to increase the risk of bone mass loss

By  

Reactions Weekly, Vol. 1, Iss. 1081, 2005-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Zoledronic acid a fast fix for AI-induced bone loss

By  

Inpharma, Vol. 1, Iss. 1620, 2008-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite

Risedronic acid: Hypocalcaemia: case report

By  

Reactions Weekly, Vol. 1, Iss. 1129, 2006-01 ,pp. : 18-19

Adis International

Access to resources Recommend Favorite